Cargando…

Effects of mitotane treatment on human steroid metabolism: implications for patient management

Mitotane (o,p'-DDD), an oral adrenolytic agent for treatment of advanced adrenocortical carcinoma (ACC), is reported to inhibit cortisol biosynthesis in vitro and enhance production from exogenous cortisol of urinary 6β-hydroxycortisol and unidentified polar unconjugated metabolites. We examine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghataore, L, Chakraborti, I, Aylwin, S J, Schulte, K-M, Dworakowska, D, Coskeran, P, Taylor, N F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioScientifica 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682235/ https://www.ncbi.nlm.nih.gov/pubmed/23781302 http://dx.doi.org/10.1530/EC-12-0028

Ejemplares similares

SAT313 Therapeutic Dosing Of Steroids In Patients On Mitotane
por: Pham, Christopher, et al.
Publicado: (2023)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
por: Bianchini, Marta, et al.
Publicado: (2021)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Effect of Mitotane on Male Gonadal Function
por: Innocenti, Federica, et al.
Publicado: (2023)

High‐Dose Mitotane‐Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
por: Pape, Elise, et al.
Publicado: (2017)

Biological response of adrenal carcinoma and melanoma cells to mitotane treatment
por: Stelcer, Ewelina, et al.
Publicado: (2022)

Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog
por: Park, Su‐Min, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Dyslipidemia causes overestimation of plasma mitotane measurements
por: Paci, Angelo, et al.
Publicado: (2016)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor
por: Oddie, Philip D, et al.
Publicado: (2018)

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2021)

Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study
por: Shawa, Hassan, et al.
Publicado: (2013)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane
por: Cantini, Giulia, et al.
Publicado: (2023)

Generation and characterization of a mitotane-resistant adrenocortical cell line
por: Seidel, Eric, et al.
Publicado: (2020)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

ODP049 Oncocytic adrenocortical carcinoma misdiagnosed as renal oncocytoma and use of urinary steroid profiling in disease monitoring after mitotane therapy
por: Wong, Cheuk Lik, et al.
Publicado: (2022)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
por: Head, Lia, et al.
Publicado: (2019)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
por: Haider, Malik Salman, et al.
Publicado: (2021)

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022)

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
por: Haak, H. R., et al.
Publicado: (1994)

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2022)

Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells
por: Bikas, Athanasios, et al.
Publicado: (2019)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
por: Alam, Walid, et al.
Publicado: (2021)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
por: Lo Iacono, Marco, et al.
Publicado: (2021)

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
por: Steenaard, Rebecca V., et al.
Publicado: (2022)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

Effect of Trilostane and Mitotane on Aldosterone Secretory Reserve in Dogs with Pituitary‐Dependent Hyperadrenocorticism
por: Reid, L.E., et al.
Publicado: (2014)

Mitotane treatment in patients with metastatic testicular Leydig cell tumor associated with severe androgen excess
por: Chortis, Vasileios, et al.
Publicado: (2018)

Effective treatment with mitotane for a canine case of presumed ectopic Cushing’s syndrome-related pheochromocytoma
por: Miura, Konatsu, et al.
Publicado: (2022)

Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study
por: Cerquetti, Lidia, et al.
Publicado: (2019)

Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series
por: Tőke, Judit, et al.
Publicado: (2022)

ODP597 Clinical case of uncomplicated pregnancy in a patient with adrenocortical carcinoma during treatment with mitotane
por: Beltsevich, Dmitry, et al.
Publicado: (2022)

THU609 Timeline For Undetectable Mitotane Plasma Levels In Adrenocortical Carcinoma Patients After Stopping Treatment
por: Younes, Nada, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g8lecgc14sqpsn4ml4b3qkfn5b